CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
Status:
Recruiting
Trial end date:
2034-12-31
Target enrollment:
Participant gender:
Summary
In this protocol, the investigators hypothesize that modifying the process of producing CAR+
T-cells can help to improve responses and reduce toxicities. Building on previous in vitro
studies that have shown successful production of CAR+ T-cells using a new production
approach, the investigators are now studying the ability to produce these CAR+ T-cells and
determine how well they work in the clinical setting.